Drug-Eluting Stent Tissue Engineering Patents: Leaders & White Space 2026
- Filing has cooled since its 2017 peak. nine families filed that year against four at the 2022 midpoint and a single filing in the most recent partial year — activity is flat to declining, not accelerating.
- Claim density sits in sterilisation and implant mechanics, not biologics. A61L (sterilising & disinfecting) and A61F (implants & prostheses) cover 78 and 64 of the 124 records; peptide/protein chemistry under C07K accounts for only 7.
- No assignee is filing at volume right now. across the tracked assignees, recent-year momentum is at most one family in the latest year — the leaderboard reflects historical filing, not current activity.
What this landscape covers
This dataset tracks 124 patent families published between 2015 and mid-2026 that combine drug-eluting or coated stent claims with bioresorbable scaffold, endothelialization-promotion, or tissue-integrating stent language. The search deliberately sits at the intersection of two established fields — drug elution and tissue engineering — rather than covering either broadly, so the counts below describe a specific, already-crowded technical niche rather than the stent market as a whole.
Filings concentrate in United States receiving office activity, with PCT and European filings well behind and a modest but real India presence. Because publication typically lags filing by around eighteen months, the low count in the most recent year understates real filing activity rather than signalling an actual falloff to zero.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 124 families: when they were filed, and which IPC subclasses carry the claim weight.
A 2017 peak followed by a decline
Filings ran at nine in 2017, fell to four by the 2022 midpoint, and sit at one in the most recent (partial) year. Read the tail end cautiously — the 18-month publication lag means 2025-2026 filings are still arriving.
Sterilisation and implant mechanics dominate
A61L (sterilising & disinfecting) and A61F (implants & prostheses) are the two largest subclasses at 78 and 64 records respectively, well ahead of A61K medicinal preparations (24) and B29C plastics shaping (15). Peptide and protein chemistry (C07K, 7) and condensation polymers (C08G, 6) are thin by comparison — high filing density in the mechanical and sterilisation classes means that claim space is occupied there, not that the biologics side is exhausted.
Shares are the percentage of the 124 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Drug-Eluting Stent Tissue Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about drug-eluting stent tissue engineering and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents
The filing describes a bioresorbable vascular stent scaffold combining a nitric oxide agonist — a statin or HMG CoA reductase inhibitor — with a lactide/glycolide/lactone polymer. The agonist can be coated on, incorporated within, or chemically bonded to the polymer, and the invention extends to a method of treating atherothrombosclerotic occlusive disease by implanting such a stent so the agonist is exuded from or released as the scaffold degrades.Filed by Palmetto Pharmaceuticals LLC, published 2012-09-27.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20100076544A1 | Biodegradable vascular support | 106 |
| 2 | US20160081824A1 | Crimping polymer scaffolds | 42 |
| 3 | US20160213499A1 | Biodegradable endoprostheses and methods for their fabrication | 38 |
| 4 | US20120290070A1 | Control Of Degradation Profile Of Bioabsorbable Poly(L-Lactide) Scaffold | 31 |
| 5 | US20150073536A1 | Assessment of a drug eluting bioresorbable vascular scafford | 23 |
| 6 | US20130238078A1 | Bioresorbable Polymer Scaffold Treatment of Coronary and Peripheral Artery Disease in Diabetic Patients | 20 |
| 7 | US20160081827A1 | Thermal processing of polymer scaffolds | 19 |
| 8 | US20160038315A1 | Treatment of cardiac diseases that promote epicardial artery enlargement with bioresorbable scaffolds | 19 |
| 9 | US20140212355A1 | Trans-arterial drug delivery | 19 |
| 10 | WO2015187659A2 | Treatment of coronary artery lesions with a scaffold having vessel scaffold interactions that reduce or preve… | 17 |
Citation counts favour older filings in any searched corpus; treat this table as a map of technical influence, not of current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three signals stand out once the raw counts are read against each other.
The peak has passed, on paper
Filings ran at nine in 2017 and have declined to a single filing in the latest partial year, with the 2022 midpoint at four. Given the typical 18-month publication lag, treat the last one to two years as undercounted rather than as proof the field has stopped moving.
Sterilisation and implant mechanics carry the claim weight
The two largest IPC subclasses, sterilising/disinfecting and implants/prostheses, together dominate the corpus. Anyone drafting new claims here is entering the most contested part of the landscape rather than open ground.
Filing strategy is US-centred
United States receiving-office filings outnumber PCT filings by more than 2.5 to 1, with Europe, India, Australia and Canada each trailing further behind. A US-first, selectively-extended filing pattern is the norm in this niche, not broad simultaneous multi-jurisdiction coverage.
Collaboration is thin and concentrated
Only eight co-assignee pairs appear across the corpus, and the strongest repeated pairings all involve the same corporate assignee working with different named inventors. This points to internal inventor teams rather than cross-company joint development as the dominant filing pattern.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to drug-eluting stent tissue engineering, with the prior art for and against each one.
Who holds the ground, and how active they are now
The assignee ranking reflects cumulative filing since 2015; recent-year momentum tells a different, quieter story.
Abbott Cardiovascular Systems
Appears repeatedly in the co-assignee pairs with named inventors (Wang Yunbing, Ma Xiao, Harrington Joel), each pairing occurring twice — consistent with an internal R&D team filing steadily rather than a single breakthrough family.
Evmoral Medical LLC
The only assignee tracked with any filing activity in the most recent year, at one family. That is a small signal given the low base, but it is the single point of current momentum in an otherwise dormant leaderboard.
Hemoteq AG
Named among the tracked assignees with no filings in the latest year, alongside academic and hospital-affiliated filers such as Chonnam National University Hospital and the South Dakota Board of Regents — all showing historical presence but no current filing activity in this dataset.
| Assignee | Recent year | YoY |
|---|---|---|
| Evmoral Medical LLC | 1 | — |
| Abbott Cardiovascular Systems Inc. | 0 | — |
| Hemoteq AG | 0 | — |
| Chonnam National University Hospital | 0 | — |
| South Dakota Board of Regents | 0 | — |
| HEART BIOTECH | 0 | — |
| Micell Technologies, Inc. | 0 | — |
| Cleveland Clinic Foundation | 0 | — |
Where to take this analysis
The landscape points to a mature, US-centred filing pattern with a thin biologics layer. Two directions follow from that.
Check the biologics-adjacent classes before drafting
C07K peptide/protein claims and C08G condensation-polymer claims sit at 7 and 6 records respectively, far below the sterilisation and implant-mechanics classes. That gap is worth testing against your own claim drafts before assuming it is occupied.
Explore the IPC breakdown in EurekaTrack whether the 2025-2026 dip is real or a lag artefact
A single filing in the latest partial year looks like a stop, but publication lag of roughly 18 months means the true 2025-2026 filing count is not yet visible in this data. Re-run the trend in a future quarter before concluding the field has gone quiet.
Monitor filing trends in EurekaCommon questions about this landscape
Abbott Cardiovascular Systems shows the most consistent filing history in this dataset, appearing in multiple co-assignee pairings with named inventors across several families. However, none of the tracked assignees, including Abbott, show filing activity in the most recent year, so the leaderboard reflects historical cumulative filing rather than a currently active leader. A practitioner should treat this as a map of who has occupied the space, not who is expanding it right now.
Based on filing trend data, activity peaked in 2017 at nine families and has since declined, with only four filed by the 2022 midpoint and one in the latest partial year. Because patent publication typically lags actual filing by around 18 months, the most recent one to two years are undercounted and should not be read as a hard stop. The honest read is that filing has slowed from its mid-2010s peak, not that the technology has been abandoned.
IPC composition data shows peptide and protein chemistry (C07K, 7 records) and condensation polymer chemistries (C08G, 6 records) are thin compared to sterilisation (A61L, 78) and implant mechanics (A61F, 64). This suggests biologically-active coating chemistries and novel polymer backbones are less contested than the mechanical scaffold and sterilisation claims that dominate the corpus. Anyone drafting new claims should verify this gap directly against recent filings rather than relying on subclass counts alone, since a thin subclass can still contain a blocking claim.
United States receiving-office filings lead at 51, followed by PCT filings at 19 and European filings at 15; India, Australia and Canada trail further behind at single digits. This points to a filing strategy centred on the US market with selective international extension rather than broad simultaneous global coverage. Companies evaluating freedom to operate outside the US, particularly in India or Canada, should check coverage carefully since filing density there is markedly lower.
US20120245677A1, assigned to Palmetto Pharmaceuticals LLC, covers a bioresorbable vascular stent scaffold that combines a nitric oxide agonist, such as a statin or HMG CoA reductase inhibitor, with a lactide-glycolide-lactone polymer, plus a method of treating atherothrombosclerotic occlusive disease with such a device. Its claims cover the agonist being coated on, incorporated within, or chemically bonded to the polymer, which is a broad set of attachment mechanisms for that specific drug class and polymer combination. Anyone working with a different drug class, a different bioresorbable polymer chemistry, or an alternative release mechanism should have room to design around it, but that needs claim-by-claim comparison rather than an abstract read.
Research Drug-Eluting Stent Tissue Engineering in depth with Eureka
Go past this page: query the whole drug-eluting stent tissue engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.